The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The current state of serum biomarkers of hepatotoxicity
Abstract
The level of serum alanine aminotransferase (ALT) activity reflects damage to hepatocytes and is considered to be a highly sensitive and fairly specific preclinical and clinical biomarker of hepatotoxicity. However, an increase in serum ALT activity level has also been associated with other organ toxicities, thus, indicating that the enzyme has specificity beyond liver in the absence of correlative histomorphologic alteration in liver. Thus, unidentified non-hepatic sources of serum ALT activity may inadvertently influence the decision of whether to continue development of a novel pharmaceutical compound. To assess the risk of false positives due to extraneous sources of serum ALT activity, additional biomarkers are sought with improved specificity for liver function compared to serum ALT activity alone. Current published biomarker candidates are reviewed herein and compared with ALT performance in preclinical and on occasion, clinical studies. An examination of the current state of hepatotoxic biomarkers indicates that serum F protein, arginase I, and glutathione-S-transferase alpha (GSTalpha) levels, all measured by ELISA, may show utility, however, antibody availability and high cost per run may present limitations to widespread applicability in preclinical safety studies. In contrast, the enzymatic markers sorbitol dehydrogenase, glutamate dehydrogenase, paraxonase, malate dehydrogenase, and purine nucleoside phosphorylase are all readily measured by photometric methods and use reagents that work across preclinical species and humans and are commercially available. The published literature suggests that these markers, once examined collectively in a large qualification study, could provide additional information relative to serum ALT and aspartate aminotransferase (AST) values. Since these biomarkers are found in the serum/plasma of treated humans and rats, they have potential to be utilized as bridging markers to monitor acute drug-induced liver injury in early clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J., & Furlong, C. E. (1996) · Nature Genetics · doi:10.1038/ng1196-334 · Cited by 603
A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters
Ramaiah, S. K. (2007) · Food and Chemical Toxicology · doi:10.1016/j.fct.2007.06.007 · Cited by 494
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., & Seeff, L. B. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.2050 · Cited by 439
Serum alanine aminotransferase in skeletal muscle diseases†
Nathwani, R. A., Pais, S., Reynolds, T. B., & Kaplowitz, N. (2005) · Hepatology · doi:10.1002/hep.20548 · Cited by 398
Zollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
Determination of paraoxonase (PON1) status requires more than genotyping
Richter, R. J., & Furlong, C. E. (1999) · Pharmacogenetics · doi:10.1097/00008571-199912000-00009 · Cited by 281
Costa, L. G., Cole, T. B., Jarvik, G. P., & Furlong, C. E. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152421 · Cited by 264
Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response
Feingold, K. R., Memon, R. A., Moser, A. H., & Grunfeld, C. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00084-7 · Cited by 248
Cited by
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Biochemical markers of muscular damage
Brancaccio, P., Lippi, G., & Maffulli, N. (2010) · cclm · doi:10.1515/cclm.2010.179 · Cited by 839
Plasma MicroRNA-122 as a Biomarker for Viral-, Alcohol-, and Chemical-Related Hepatic Diseases
Zhang, Y., Jia, Y., Zheng, R., Guo, Y., Wang, Y., Guo, H., Fei, M., & Sun, S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147850 · Cited by 415
Current Developments in Salivary Diagnostics
Miller, C. S., Foley, J. D., Bailey, A. L., Campell, C. L., Humphries, R. L., Christodoulides, N., Floriano, P. N., Simmons, G., Bhagwandin, B., Jacobson, J. W., et al. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.68 · Cited by 389
Lowes, D. A., Webster, N. R., Murphy, M. P., & Galley, H. F. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aes577 · Cited by 314
Antoine, D. J., Jenkins, R. E., Dear, J. W., Williams, D. P., McGill, M. R., Sharpe, M. R., Craig, D. G., Simpson, K. J., Jaeschke, H., & Park, B. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.019 · Cited by 309
RetractedMomen-Heravi, F., Saha, B., Kodys, K., Catalano, D., Satishchandran, A., & Szabo, G. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0623-9 · Cited by 307
Clinical Biochemistry of Hepatotoxicity
P Sharma, O. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.s4-001 · Cited by 305
Lowes, D. A., Thottakam, B. M. V., Webster, N. R., Murphy, M. P., & Galley, H. F. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.003 · Cited by 261
Models of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127
Gonzalez, E., van Liempd, S., Conde-Vancells, J., Gutierrez-de Juan, V., Perez-Cormenzana, M., Mayo, R., Berisa, A., Alonso, C., Marquez, C. A., Barr, J., et al. (2012) · Metabolomics · doi:10.1007/s11306-011-0329-9 · Cited by 69
Oloya, B., Namukobe, J., Ssengooba, W., Afayoa, M., & Byamukama, R. (2022) · Tropical Medicine and Health · doi:10.1186/s41182-022-00406-7 · Cited by 65
Muller, P. Y., & Dieterle, F. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903114174 · Cited by 62
Clarke, J. I., Dear, J. W., & Antoine, D. J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1160057 · Cited by 46
Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis
Ippolito, D. L., AbdulHameed, M. D. M., Tawa, G. J., Baer, C. E., Permenter, M. G., McDyre, B. C., Dennis, W. E., Boyle, M. H., Hobbs, C. A., Streicker, M. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfv214 · Cited by 43
Kaminsky-Kolesnikov, Y., Rauchbach, E., Abu-Halaka, D., Hahn, M., García-Ruiz, C., Fernandez-Checa, J. C., Madar, Z., & Tirosh, O. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5393761 · Cited by 39
Ribeiro, C. B., Ramos, F. M., Manthey, J. A., & Cesar, T. B. (2019) · Phytotherapy Research · doi:10.1002/ptr.6386 · Cited by 33
Buness, A., Roth, A., Herrmann, A., Schmitz, O., Kamp, H., Busch, K., & Suter, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097249 · Cited by 26
Qazi, M. R., Hassan, M., Nelson, B. D., DePierre, J. W., & Abedi-Valugerdi, M. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2012.12.001 · Cited by 21
Metadata
- Authors
- Ozer, J., Ratner, M., Shaw, M., Bailey, W., & Schomaker, S.
- Venue
- Toxicology
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 245
- Issue
- 3
- Pages
- 194-205
- ISSN
- 0300-483X (ISSN-L)
- OpenAlex
- W2047718984
- Cited by
- 1,269
- References
- 42
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.